EVAX
Evaxion A/SPrice
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Mar 5 ▲ Evaxion reported strong 2025 financial and clinical progress, highli…
- Mar 10 Jones Trading initiates
- Apr 7 ▲ Evaxion announced the successful completion of the one-year extensio…
- Apr 17 ▲ Evaxion announced new Phase 2 data for its AI-designed personalized…
- Apr 17 ▲ Evaxion announced new data from a collaboration with Duke University…
- Jul 17 ▲ Evaxion announced it will present three-year clinical efficacy data…
- Aug 31 ▼ Short interest jumps 172.7% to 56.5K
- Oct 15 ▼ Short interest jumps 32.6% to 67.0K
- Oct 19 ▲ Evaxion reported that all patients in the phase 2 trial of personali…
- Oct 23 ▲ Evaxion reported three-year follow-up data from its Phase 2 trial of…
- Oct 30 ▲ Short interest falls 58.9% to 27.6K
Signal stack
Where each data set points today.
- InstitutionsMIXED
Q3 2026: 1 added (0 new), 1 trimmed or exited.
- EstimatesFLAT
Current-quarter EPS estimate −$0.010 → −$0.010 over 90 days.
- Short sellersCOVERING
Short interest −58.9% to 27.6K shares. 1.0 days to cover, ≈0.3% of shares.
- TrendDOWNTREND
11% below its 50-day average. New closing low $2.74 on Nov 13.
- SocialQUIET
No Reddit mentions this week. Last mention Nov 3.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | ADD | $151.5K |
| UBS Group AG | NEAR_EXIT | $3.1K |
| CITADEL ADVISORS LLC | DOUBLED | $113.4K |
| RHUMBLINE ADVISERS | DOUBLED | $100.6K |
| UBS Group AG | DOUBLED | $15.3K |
| UBS Group AG | NEAR_EXIT | $4.00 |
| RHUMBLINE ADVISERS | DOUBLED | $23.1K |
| UBS Group AG | TRIM | $5.0K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
Last action Apr 2026Price is below the lowest target. Median implies +333%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Apr 24, 2026 | HC Wainwright & Co. REITERATE | Buy |
| Mar 10, 2026 | Jones Trading INITIATE | Buy |
| Mar 9, 2026 | Lake Street MAINTAIN | Buy |
| Mar 9, 2026 | HC Wainwright & Co. REITERATE | Buy |
| Oct 30, 2025 | Edward Jones INITIATE | Buy |
| Oct 20, 2025 | Lake Street MAINTAIN | Buy |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.01 | -$0.01–-$0.01 | +0.0% | $0.00 |
| Next Q | -$0.01 | -$0.01–-$0.01 | +0.0% | $0.00 |
| Current FY | -$0.04 | -$0.04–-$0.04 | +0.0% | $0.00 |
| Next FY | -$0.01 | -$0.03–$0.00 | +0.0% | $4.7M |
Short side
FINRA· Oct 30, 2026SecBot reports
30 filings · 20 press releases · 6 bullish · 1 bearish · 23 neutral- NEUTRAL 6-KNov 12, 2026
Evaxion A/S filed a Form 6-K announcing its 2027 financial calendar, which includes dates for…
Monitor the March 4, 2027 business update for full-year 2026 financial results and any pipeline or partnership updates. No immediate catalyst from this filing.
- NEUTRAL PRESS RELEASENov 12, 2026
Evaxion published its 2027 financial calendar, listing dates for business updates, annual general…
No material information for trading. Monitor the March 4, 2027 business update for full year 2026 financial results and any pipeline or partnership updates.
- NEUTRAL 6-K, F-1/A, PRESS-RELEASENov 9, 2026
Evaxion filed Amendment No. 1 to its F-1 registration statement and a related 6-K press release on…
Monitor SEC effectiveness of the F-1 registration statement, which would allow EIB to begin selling shares. Watch for any EIB sales that could create overhang on EVAX stock given the 38.45 million…
- NEUTRAL 6-KNov 6, 2026
Evaxion announced new biomarker data from its phase 2 trial of personalized cancer vaccine EVX-01…
The biomarker data strengthens the scientific case for EVX-01 and the AI-Immunology platform, but the company remains a pre-revenue clinical-stage biotech with a $27M market cap. Watch for…
All EVAX filing & press-release reports (50)
- 6-K reportNov 12, 2026
- PRESS-RELEASE reportNov 12, 2026
- 6-K, F-1/A, PRESS-RELEASE reportNov 9, 2026
- 6-K reportNov 6, 2026
- PRESS-RELEASE reportNov 6, 2026
- 6-K reportNov 4, 2026
- 6-K reportNov 4, 2026
- 6-K reportNov 3, 2026
- 6-K reportOct 30, 2026
- PRESS-RELEASE reportOct 30, 2026
- 6-K reportOct 23, 2026
- 6-K reportOct 19, 2026
- 6-K reportOct 2, 2026
- PRESS-RELEASE reportOct 2, 2026
- 6-K reportSep 14, 2026
- 6-K reportSep 4, 2026
- 6-K reportAug 20, 2026
- PRESS-RELEASE reportAug 20, 2026
- 6-K reportAug 17, 2026
- 6-K reportAug 14, 2026
- PRESS-RELEASE reportAug 14, 2026
- 6-K reportJul 17, 2026
- PRESS-RELEASE reportJul 17, 2026
- 6-K reportJul 13, 2026
- PRESS-RELEASE reportJul 12, 2026
- 6-K reportJul 1, 2026
- PRESS-RELEASE reportJul 1, 2026
- 6-K reportJun 12, 2026
- PRESS-RELEASE reportJun 12, 2026
- 6-K reportJun 11, 2026
- PRESS-RELEASE reportJun 11, 2026
- PRESS-RELEASE reportMay 12, 2026
- 6-K reportMay 12, 2026
- 6-K reportMay 7, 2026
- PRESS-RELEASE reportMay 4, 2026
- 6-K reportApr 27, 2026
- PRESS-RELEASE reportApr 27, 2026
- 6-K reportApr 22, 2026
- 6-K reportApr 17, 2026
- 6-K reportApr 17, 2026
- PRESS-RELEASE reportApr 17, 2026
- PRESS-RELEASE reportApr 17, 2026
- 6-K reportApr 16, 2026
- PRESS-RELEASE reportApr 16, 2026
- PRESS-RELEASE reportApr 7, 2026
- PRESS-RELEASE reportMar 19, 2026
- PRESS-RELEASE reportMar 17, 2026
- PRESS-RELEASE reportMar 5, 2026
- PRESS-RELEASE reportMar 5, 2026
- PRESS-RELEASE reportMar 2, 2026